GLAXO
Invest with MTF
Invest Now
Invest in GlaxoSmithKline Pharmaceuticals with 3.23X leverage
Performance
- Low
- ₹2,585
- High
- ₹2,669
- 52 Week Low
- ₹1,968
- 52 Week High
- ₹3,516
- Open Price₹2,645
- Previous Close₹2,669
- Volume61,048
- 50 DMA₹2,487.67
- 100 DMA₹2,557.64
- 200 DMA₹2,627.58
Investment Returns
- Over 1 Month + 9.51%
- Over 3 Month + 4%
- Over 6 Month -6.43%
- Over 1 Year + 29.8%
Smart Investing Starts Here Start SIP with GlaxoSmithKline Pharmaceuticals for Steady Growth!
GlaxoSmithKline Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 43
- PEG Ratio
- 2.3
- Market Cap Cr
- 43,951
- P/B Ratio
- 25.7
- Average True Range
- 81.64
- EPS
- 59.37
- Dividend Yield
- 1.6
- MACD Signal
- 19.01
- RSI
- 59.73
- MFI
- 69.83
GlaxoSmithKline Pharmaceuticals Financials
GlaxoSmithKline Pharmaceuticals Technicals
EMA & SMA
Current Price
₹2,594.40
-74.1
(-2.78%)
- Bearish Moving Average 5
- Bullish Moving Average 11
- 20 Day
- ₹2,494.66
- 50 Day
- ₹2,487.67
- 100 Day
- ₹2,557.64
- 200 Day
- ₹2,627.58
Resistance and Support
2615.9
- R3 2,730.70
- R2 2,699.60
- R1 2,647.00
- S1 2,563.30
- S2 2,532.20
- S3 2,479.60
GlaxoSmithKline Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
GlaxoSmithKline Pharmaceuticals F&O
About GlaxoSmithKline Pharmaceuticals
- NSE Symbol
- GLAXO
- BSE Symbol
- 500660
- Managing Director
- Mr. B Akshikar
- ISIN
- INE159A01016
Similar Stocks to GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals FAQs
GlaxoSmithKline Pharmaceuticals share price is ₹2,594 As on 14 February, 2026 | 13:14
The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹43950.7 Cr As on 14 February, 2026 | 13:14
The P/E ratio of GlaxoSmithKline Pharmaceuticals is 43 As on 14 February, 2026 | 13:14
The PB ratio of GlaxoSmithKline Pharmaceuticals is 25.7 As on 14 February, 2026 | 13:14
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.